FDA has approved once-daily phentermine and topiramate extended-release (Qsymia, Vivus) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least 1 weight-related comorbidity.
FDA has approved once-daily phentermine and topiramate extended-release (Qsymia, Vivus) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least 1 weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia).
Last month, Formularyreported that FDA approved lorcaserin (Belviq, Arena Pharmaceuticals and Eisai) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes).
The combination of phentermine and topiramate for weight loss is quite interesting, according to Formulary advisor James M. Wooten, PharmD, associate professor, department of medicine, section of clinical pharmacology, University of Missouri-Kansas City. “The anorectic effect of phentermine is probably a result of its action on the hypothalamus where it stimulates the release of norepinephrine,” Dr Wooten said. “The weight loss mechanism of action of topiramate, an anticonvulsant used to treat seizures, migraine headaches, etc., is less clear but it may be due to topiramate’s ability to reduce gastrointestinal motility which results in reduced satiety.
“Studies have shown a weight reduction of 10% to 15% in 56 weeks in obese patients. It may also have positive effects on type 2 diabetes as well as dyslipidemia. Clinical studies have demonstrated a positive safety profile for this combination drug, which may be due to the relatively low dosages of each of its constituents,” Dr Wooten continued. “That being said, efficacy and safety must be demonstrated over a longer period of time in various patient types before this agent can be recommended as a first-line weight loss drug.”
"Qsymia is the first FDA-approved once daily combination treatment for patients struggling with obesity," Peter Tam, president of Vivus, said in a press release. "The degree and severity of obesity and the lack of effective pharmacological interventions that we face as a society were two primary reasons for the development of Qsymia. We are pleased with FDA's decision today because patients and physicians now have another treatment option available to them. It is expected that Qsymia will be available in the fourth quarter of 2012."
The safety and efficacy of phentermine and topiramate extended-release were evaluated in 2 multicenter, phase 3 trials that included severely obese patients (the EQUIP study), and overweight or obese patients with at least 2 weight-related comorbidities, such as hypertension, hypertriglyceridemia, type 2 diabetes, or central adiposity (the CONQUER study). The average weight loss in EQUIP was 10.9% on phentermine and topiramate extended-release 15 mg/92 mg and 1.6% for placebo (ITT-LOCF, P<.0001). The average weight loss in CONQUER was 9.8% on phentermine and topiramate extended-release 15 mg/92 mg, 7.8% on phentermine and topiramate extended-release 7.5 mg/46 mg and 1.2% for placebo (ITT-LOCF, P<.0001).
The most common adverse reactions for patients treated with phentermine and topiramate extended-release included tingling sensation of hands and feet, dizziness, altered taste, insomnia, constipation, and dry mouth.
Phentermine and topiramate extended-release was approved with a Risk Evaluation and Mitigation Strategy (REMS) with a goal of informing prescribers and female patients of reproductive potential about an increased risk of orofacial clefts in infants exposed to phentermine and topiramate extended-release during the first trimester of pregnancy, the importance of pregnancy prevention for females of reproductive potential receiving phentermine and topiramate extended-release and the need to discontinue phentermine and topiramate extended-release immediately if pregnancy occurs. The phentermine and topiramate extended-release REMS program includes a Medication Guide, Healthcare Provider training, distribution through certified pharmacies, implementation system and a timetable for assessments.
As part of the approval of phentermine and topiramate extended-release, Vivus is committed to conduct post-marketing studies. The company will conduct a study to assess the long-term treatment effect of phentermine and topiramate extended-release on the incidence of major adverse cardiovascular events in overweight and obese subjects with confirmed cardiovascular disease, studies to assess the safety and efficacy of phentermine and topiramate extended-release for weight management in obese pediatric and adolescent subjects, studies to assess drug utilization and pregnancy exposure, a study to assess renal function, as well as animal and in vitro studies.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.